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Insulin, thyroid stimulating hormone and lipid levels among  obese adult 
males in Gaza Governorate. 
 Abstract 
 
Objective: This study aimed to asses the levels of insulin, thyroid stimulating 
hormone (TSH), glucose and lipid profile among obese adult males in Gaza 
Governorate. The relation between such parameters and obesity grades as 
well as between insulin, TSH and the other parameters were established. 
Methodology: The study sample comprised 82 obese males aged between 
20-40 years. The control group consisted of 82 non-obese individuals 
matched cases with age. TSH and insulin levels were determined using 
ELISA technique while lipid profile and glucose assayed by enzymatic 
methods. Demographic and personal data were collected using questionnaire 
interview. Data were analyzed using SPSS program. 
Results: Obesity was significantly related to history of hyperlipidemia, 
inappropriate weight gain and family history (p<0.05).  Getting fatigue quickly, 
muscle weakness and consumption of marine food, and large quantities of 
carbohydrates and lipids-rich food were significantly  related to obesity. 
Walking regularly and having active job were also related to obesity. The 
mean levels of insulin and glucose were significantly increased in cases 
compared to controls (mean=13.0±13.0 ìIU/mL and 91.0±20.2 mg/dl Vs 
6.9±8.0 ìIU/mL and 83.7±11.2 mg/dl, P=0.000 and 0.005, respectively). In 
contrast, the mean levels of TSH were lower in cases compared to controls                                              
(mean = 1.41±1.23 ìIU/mL Vs 1.93±0.98 ìIU/mL, P=0.003). The mean  levels 
of total cholesterol, triglycerides and  LDL  were increased in cases compared 
to controls (mean=187.3±38.5 mg/dl,139.2±63.7mg/dl and119.4±34.8 mg/dl 
Vs174.9±43.5 mg/dl, 98.9±68.6 mg/dl and 107.9±42.4 mg/dl, respectively), 
whereas the mean level of HDL was significantly decreased in cases 
compared to controls (40.1±10.9 mg/dl Vs 47.7±9.6 mg/dl). There were no 
significant relations between the studied parameters including insulin, TSH, 
glucose, total cholesterol, triglyceride, LDL and HDL, and different grades of 
obesity. The increases in the mean levels of insulin throughout the three 
categories of< 9, 9-18 and >18 ìIU/mL were significantly associated with 
 V
increasing glucose levels (F=5.619, P=0.005). On the other hand, the relation 
of insulin with other parameters was not significant (P>0.05). There was no 
significant relation between TSH and other parameters ( P>0.05). Insulin level 
showed strong positive correlation with glucose level (r=0.470). This 
correlation was significant (P=0.000). TSH level showed relatively weak 
negative correlations with total cholesterol and LDL levels (r=-0.233, r=-0.227, 
respectively). Such correlations were significant with P=0.036 and P=0.041, 
respectively. 
Recommendations: We recommend that obese individuals must follow diet 
and do exercise to reduce weight  in order to  avoid dangerous  diseases. 
Insulin test is a very important test for obese individuals; this test may predict 
if the obese person is pre-diabetic or not and frequent monitoring of lipid 
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                             1. Introduction 
1.1  Overview 
Obesity can lead to several diseases that impact negatively on quality of life,   
morbidity and mortality outcomes in large population groups (1). Obesity is 
associated with a wide variety of co-morbidities, some of which may lead to    
disability or death (2). Approximately 1.2 billion people in the world are 
overweight and at least 300 million of them are obese. According to the World 
Health Organization (WHO), obesity is one of the 10 most preventable health 
risks, and  the frequency of obesity around the world is 25 percent where 10 
percent of those, morbid obeses, have body mass index (BMI) >39 (3). 
Thyroid hormones affect in a myriad of biological processes such as 
development, growth and metabolic control, as it influence all major metabolic 
pathways (4).  
 
Their most obvious and well-known action is an increase in basal energy 
expenditure obtained acting on protein, carbohydrate and lipid metabolism. 
With specific regard to lipid metabolism, thyroid hormones affect synthesis, 
mobilization and degradation of lipids, although degradation is influenced 
more than synthesis (5). The association of obesity with type 2 diabetes has 
been recognized for decades, and the major basis for this link is the ability of 
obesity to engender insulin resistance (6).          
 
There are also grounds for considering the related possibility that insulin 
resistance and hyperinsulinemia, in addition to being caused by obesity, can 
contribute to the development of obesity (7). The relationship between obesity 
and insulin resistance is seen across all ethnic groups and is evident across 
the full range of body weights (8). Central (intra-abdominal) depots of fat are 
much more strongly linked to insulin resistance, type 2 diabetes, and 
cardiovascular disease than are peripheral (subcutaneous) fat depots (9).  It is 
possible that an unknown common factor, either genetic or environmental, 
produces both insulin resistance and the central pattern of regional adiposity, 
and that central obesity does not actually cause insulin resistance. 
 
Alternatively, some biochemical feature of intra-abdominal adipocytes may 
directly influence systemic insulin  sensitivity (7). 
        
The relationship between obesity, lipid profile, insulin levels and thyroid 
dysfunction is a concern for researchers, and studies are being carried out to 
link up these variables. Lipid and thyroid profiles are the most common 
investigations called for in obese subjects by clinicians (10,11). Obesity is 
associated with derangements in the lipid profile, which further increases the 
risk of coronary heart disease, diabetes mellitus, stroke and certain cancers.  
In some studies, higher total cholesterol (TC) , Triacylglycerol (TAG) , low 
density lipoprotein cholesterol (LDL-C) and very low density lipoprotein 
cholesterol (VLDL-C) levels were observed in obese subjects as compared to 
controls except high density lipoprotein cholesterol ( HDL-C) , which was 
significantly lower in obese subjects (12). When the TSH levels were 
correlated among the obese subjects with grade I and grade II obesity 
according to BMI values, a significant difference  in TSH levels were observed, 
highlighting the variation in TSH levels depending on the extent of obesity (12).  
 
Other previous studies, reported that an increase in BMI was associated with 
an increase in TG, and a decrease in HDL-C levels (13,14, 15). Early studies 
also revealed  an association between body mass index (BMI) and TSH levels, 
showing varying TSH levels depending on the degree of obesity from mild to 
severe (16). As the lipid profile is deranged with higher BMI, it impairs 
resistance to TSH in peripheral tissue and further aggravating the thyroid 
problem (12). Hypothyroidism is linked to obesity, and so there must be some 
link between the thyroid profile and the lipid profile, as derangements of lipid 
profile are observed in obesity (14,15). 
 
In the European population, a positive correlation has been established 
between obesity (BMI > 30 kg/m2) and TSH level (17). In a study on 226 
euthyroid obese or over weight female patients there was significant positive 
correlation between serum TSH and fasting plasma insulin (18). The 
association between normal range thyroid function and BMI and dyslipidemia 
has been the subject of much debate. A study showed a positive correlation 
 
between BMI and serum TSH, a negative correlation between BMI and serum 
free T4, and no association between BMI and serum free T3 (19). Other study 
in obese women without complications also showed a positive correlation 
between normal range serum TSH and BMI (20).  
 
However, investigation of another cohort 401 euthyroid subjects showed no 
significant relationship between BMI and either serum TSH concentration or 
free T4 (21). These findings  suggest that thyroid function within the normal 
range may be associated with BMI, but a definitive relationship is not clear at 
this point(22). While some studies have found that thyroid disorders may lead 
to obesity, recent studies on obese children showed that it is the obesity that 
may cause the disorder. In a recent study dealt with the alterations in thyroid 
function and structure these alterations are common in obese children.                               
An association between body mass index and thyroid hormone levels was 
found. This suggests that fat excess may have a role in thyroid tissue 
modification and thyroid function has been shown to return to normal after 



















The overall objective is to asses insulin, thyroid stimulating hormone, glucose 
and lipid levels among obese adult males in Gaza Governorate.  
The specific objectives are: 
1. To asses risk factors of obesity 
2. To determine insulin, glucose  and TSH levels among obese adults in 
comparison to non obese individuals. 
3. To determine total cholesterol, Triacylglycerol, high-density lipoprotein 
cholesterol, and low density lipoprotein cholesterol among the obese and non 
obese individuals. 
4. To evaluate the relationship between obesity grades and insulin, TSH, 
glucose and lipid profile. 
5. To find out the relation between insulin, TSH, and the other studied 
parameters   
 
1.3  Significance 
1. Obese subjects may present with abnormal thyroid function, but reported 
data in Gaza governorate are scarce. 
2. Examination of TSH is required in obese subjects in an attempt to  
understand the underlying cause of obesity.  
3. To make obese subjects aware of risk factors of obesity. 
4. Some obese people have insulin resistance (pre-diabetic) but dont even 
know, by maintaining an appropriate weight and active life style, many 
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                        2. Literature review 
2.1 Obesity 
2.1.1  Definition 
Obesity is defined as an excess accumulation of body fat and is known to 
increase the risk of various pathological states such as hypertension, 
dyslipidemia and coronary heart disease (25). Obesity, especially abdominal 
obesity is a very important risk factor of cardiovascular  diseases and some 
types of cancer. It is also conducive to the development of metabolic and 
rheumatic diseases, diseases of the liver and biliary ducts, as well as 
respiratory diseases (26).  Obesity is the consequence of an overall positive 
energy balance maintained over time, that is, the metabolizable energy intake 
exceeds the energy expenditure for basal metabolic requirements, 
thermoregulation, physical activity, and growth (27). 
   
2.1.2  Chemical factors affecting obesity 
There is a number of naturally occurring chemicals involved in monitoring 
energy levels, energy expenditure, or current energy supplies. Among the 
factors that relay this information are both the neurotransmitters  including 
serotonin, dopamine,  epinephrine, and histamine, as well as other factors 
that relay messages about food intake and energy levels such as leptin, 
cholecystokinin (CCK), neuropeptide Y(NPY), ghrelin, agouti-related peptide 
(AgRP), and adiponectin (28). These chemicals are some of the messengers 
that constantly relay information regarding the body's levels of available and 
stored energy to the brain, and there is significant redundancy in their effects. 
For example, cholecystokinin, adiponectin, leptin, serotonin, and histamine all 
suppress appetite, whereas ghrelin, agouti related protein, and neuropeptide 
Y all increase appetite (28) . 
 
2.1.3  Causes of obesity  
1- Genetics: The role of a genetic predisposition to obesity has long been 
recognized to affect both terms (intake and expenditure) of the energy 
balance equation (29). Genes may influence afferent and efferent signals as 
 
well as central mechanisms involved in body-weight regulation (30,31). An 
update of the genetics of human obesity revealed that the numbers of genes 
or markers that have been linked with human obesity are increasing rapidly 
and now approaching 200 genes (32,33). The possible physiological 
mechanisms through which a genetic susceptibility may be operating include 
low resting metabolic rate, low rates of oxidation, low fat-free mass and 
altered food intake, as well as other factors related to macronutrient utilization, 
energy expenditure or the hormonal profile, including insulin sensitivity (34,25). 
The occurrence of genes or mutations responsible for the susceptibility of 
some individuals or groups of individuals to gain weight in the presence of an 
energy-dense diet or a reduced daily physical activity is being currently 
investigated (35,36). 
 
2- Physical inactivity: Most available evidence suggests that a lower activity-
related energy expenditure is an important contributor to the increasing 
prevalence of obesity, although a blunted response to food intake and 
reductions in resting energy expenditure may have an impact on weight gain 
(37,38). Furthermore, studies have often found an associations between 
leisure-time physical activity (inverse) or total amount of time spent sitting 
down (direct) and BMI (39), while a low participation in sports activities, a lack 
of interest in taking exercise and a high number of hours spent sitting down at 
work are statistically significant predictors of obesity (40).  
 
3- Overeating: Overeating is a relative term. It refers to the consumption of 
an energy intake that is inappropriately large for a given energy expenditure, 
thus, leading to obesity, Physical inactivity compounds the effects of high-fat, 
energy-dense diets, causing positive energy balance (41). 
 
4- Diseases: Diseases such as hypothyroidism, insulin resistance, polycystic 
ovary syndrome and Cushing's syndrome, are also contributors to obesity (42). 
5- Psychological factors: A variety of psychosocial factors contribute to the 
development of obesity and to the difficulty of losing weight. For some people, 
 
emotions influence eating  habits. Many people eat excessively in response to 
emotions such as boredom, sadness, stress or anger (43) . 
6- Medications : Medications  are documented to increase weight  gain 
include antipsychotics (phenothiazines, butyrophenones), antidepressants, 
antiepileptics, insulin and some oral hypoglycemics. Whereas most of these 
medications contribute modestly to obesity, the large doses of steroids 
sometimes used  to treat  autoimmune  diseases or used as contraceptive  
can cause true obesity (44). 
 
2.1.4  Classification  and assessment of obesity 
The initial step in evaluation of obesity is the calculation of BMI. To measure 
BMI, one begins by weighing the patient in underclothes and without shoes. 
Height as well measured without shoes. BMI is calculated by dividing weight 
(in kilograms), by square height (in meters). BMI has replaced percentage 
ideal body weight as a criterion for assessing obesity for several reasons. BMI 
correlates significantly with body fat, morbidity, and mortality, and it can be 
calculated quickly and easily. Furthermore, recommendations for treatment of 
obesity are based on BMI. A BMI of 25 kg/m2 is the generally accepted 
threshold for identifying a patient at higher risk for obesity-related diseases, 
most notably type 2 diabetes, hypertension, and cardiovascular disease (45). 
Risk of death begins to increase at a BMI of 23 kg/m2 when compared with 
the lowest risk group (BMI, 19.0 to 21.9 kg/m2) (46). 
 
 Medical risk rises progressively with increasing degrees of obesity beginning 
with overweight, defined by BMI between 25.0 and 29.9 kg/m2, through class 
I obesity (BMI, 30.0 to 34.9 kg/m2), class II obesity (BMI, 35.0 to 39.9 kg/m2), 
and class III or morbid obesity (BMI > 40 kg/m2) (47). This classification 
system of obesity by BMI was developed by the World Health Organization 
Obesity Task Force and has been adopted by researchers on the 
identification, evaluation, and treatment of overweight and obesity in adults 
(48,49). Waist circumference is an important measure of obesity risk. The 
measuring tape should be snug but not compressing the skin and held parallel 
to the floor. The measurement is made at normal respiration (49). A high-risk 
 
waist circumference is accepted to be 35  inches (88 cm) or greater for 
women and 40 inches (102 cm ) or greater for men. Waist circumference is a 
practical indicator of visceral abdominal fat. Evidence suggests that 
abdominal fat carries a higher health risk than peripheral fat, and that the 
visceral fat component correlates the most strongly with increased risk (49). 
Some epidemiological studies have found the waist-to-hip ratio to correlate 
with increased risk for diabetes, coronary heart disease(CHD), and 
hypertension (49), however, this measure is not established as an 
independent risk factor. Waist circumference also has been found to be a 
superior indicator of abdominal fat distribution (49). 
 
 The truncal fat distribution indicated by an increased waist circumference 
correlates with the hypertrophic form of obesity. Hypercellular obesity, which 
is characterized by an increased total number of fat cells, typically affects 
patients with a BMI less than 40 kg/m2 but may be a lower risk form of 
disease. In hypertrophic obesity, existing fat cells enlarge and produce 
proteins and metabolites` involved in the pathophysiology of obesity (50). 
These proteins include lipoprotein lipase, which contributes to hydrolysis of 
the triglycerides of very-low-density lipoproteins (VLDL) and chylomicrons, 
and cytokines (tumor necrotizing factor-and interleukin-6), as well as resistin 
(51). The hypertrophied fat cell also produces leptin hormone. Hypertrophic 
obesity correlates with metabolic complications of obesity, including impaired 
glucose tolerance, adverse lipid profile, hypertension, and CHD (50). Also, 
age of onset helps to distinguish hypercellular from hypertrophic obesity, 
because the hypercellular form often begins in childhood, whereas 
hypertrophic obesity often begins in adulthood (52). 
 
2.2 Insulin  
 
2.2.1 Definition and structure 
Insulin is a small protein; human insulin has a molecular weight of 5808. It is 
composed of two amino acid chains, connected to each other by disulfide 
linkages (figure 2.1.A) . When the two amino acid chains are split apart, the 
functional activity of the insulin molecule is lost. Insulin is synthesized in the 
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pancreatic beta cells by the usual cell machinery for protein synthesis 
beginning with the translation of the insulin RNA by ribosomes attached to the 
endoplasmic reticulum to form an insulin preprohormone. This initial 
preprohormone is cleaved in the endoplasmic reticulum to form proinsulin. 
Most of this is further cleaved in the Golgi apparatus to form insulin and 
peptide fragments before being packaged  in the secretory granules (figure 
2.1.B)  (53). 
       Figure 2.1 A. Structure of insulin. B. Formation of human insulin from preproinsulin 
 
2.2.2 Secretion  
Insulin, a hormone secreted by the beta cells of the pancreas, plays a 
predominant role in the lipogenic process (54). 
 
2.2.3 Insulin receptors 
The insulin receptor is a large transmembrane glycoprotein found in insulin 
sensitive target cells (liver, muscle, and fat) (55). It comprises two 
extracellular R-subunits that contain the insulin-binding domain and two 
membrane spanning subunits that contain a ligand activated tyrosine kinase, 
which will be referred to as the insulin receptor tyrosine kinase . Insulin acts 
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by binding to the extracellular domain of the insulin receptor, thus inducing 
autophosphorylation and activation of the insulin receptor tyrosine kinase. A 
cascade of signaling events is initiated leading to increased tyrosine 
phosphorylation of multiple intracellular substrates, including the insulin 
receptor substrates 1 and 2 , and the activation of second messenger 
systems such as phosphatidylinositol 3-kinase (56). These pathways act to 
trigger the translocation of glucose transporters 4 (GLUT4) to the cell surface 
(57). GLUT4 is one of a family of membrane proteins responsible for glucose 
uptake in mammalian cells and is the major isoform responsive to insulin 
stimulation (figure.2.2) ( 58) . 
Figure 2.2  Insulin causes cells to recruit transporters from intracellular stores. 
 
2.2.4 Increased blood glucose stimulates insulin secretion  
At the normal fasting level of blood glucose of 70 to 110 mg/dl, the rate of 
insulin secretion is minimal on the order of 25 ng/min/kg of body weight, a 
level that has only slight physiologic activity. If the blood glucose 
concentration is suddenly increased to level two to three times normal and 
kept at this high  level  thereafter, insulin secretion is increased markedly in 
two stages : 
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1. Plasma insulin concentration increases almost 10-fold within 3 to 5 minuets 
after the acute elevation of blood glucose; this results from immediate 
dumping of preformed insulin from the beta cells of the islet of langerhans.  
However the initial high rate of secretion is not maintained; instead, the insulin 
concentration decreases about halfway back toward normal in another 5 to 10 
minutes. 
2. Beginning at about 15 minuets, insulin secretion rises  a second time  and 
reaches anew plateau in 2 to 3 hours, this time usually at the rate  even 
greater than that in the initial phase. This secretion results both from 
additional release of preformed insulin and from activation of the enzyme 
system that synthesizes and releases new insulin from the cells (53).  
 2.2.5  Mechanism  of action of insulin 
The net effect of insulin is to enhance storage and block mobilization and 
oxidation of fatty acids. Insulin exerts its effect by stimulating lipoprotienlipase 
(LPL) formation, so that circulating triglycerides are hydrolyzed and free fatty 
acids can enter the adipocyte. Insulin is also required for the transport of 
glucose, which is needed for re-esterification of the triglycerides once inside 
the adipocyte. Finally, the conversion of glucose to fatty acids is accomplished 
by insulin's activation of several enzymes (54). 
Lipolysis is the chemical decomposition and release of fat from adipose tissue. 
This process predominates over lipogenesis when additional energy is 
required. The triglycerides within the adipocyte are acted upon by a multi-
enzyme complex called hormone sensitive lipase (HSL), which hydrolyzes the 
triglyceride into free fatty acids and glycerol. These lipases act consecutively 
on triglycerides, diglycerides, and monoglycerides. Insulin reduces 
mobilization of fatty acids from adipose tissue by inhibiting triglyceride lipase. 
The mechanism of this inhibition may be through a decrease in cyclic AMP 
which in turn results in an inhibition of cyclic-AMP-dependent protein kinase 
(54). 
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2.2.6 Insulin resistance and obesity 
The term insulin resistance usually connotes resistance to the effects of 
insulin on glucose uptake, metabolism, or storage. Insulin resistance in 
obesity and type 2 diabetes is manifested by decreased insulin-stimulated 
glucose transport and metabolism in adipocytes and skeletal muscle and by 
impaired suppression of hepatic glucose output (59). 
 
Insulin resistance is traditionally assessed by insulins ability to promote 
normal glucose metabolism. Insulins action on lipid metabolism is analogous 
to its role in glucose metabolism, ie, promoting anabolism and inhibiting 
catabolism. Specifically, insulin upregulates LPL and stimulates gene 
expression of intracellular lipogenic enzymes, such as acetyl-CoA carboxylase 
(ACC) and fatty acid synthase (FAS)(60). In addition, insulin inhibits adipocyte 
HSL through inhibition of its phosphorylation (61) .  
In the insulin-resistant state, the responses of both LPL and HSL to insulin are 
blunted. Thus, with insulin resistance, inefficient trapping of dietary energy 
occurs both because of decreased LPL-mediated lipolysis of chylomicron-TAG 
and ineffective inhibition of HSL-mediated lipolysis in adipose tissue (62).  
 
In obesity the fat cells, perhaps because they are already overloaded with 
TAG, fail in their normal role of protecting other tissues from the daily influx of 
dietary fatty acids. The increased flux of fatty acids (both as non-esterified and 
TAG) in the circulation has acute adverse effects on insulin sensitivity, but 
also leads in the longer  term to accumulation of (TAG) in glucose-
metabolizing tissues such as skeletal muscle, liver and the pancreatic â-cell 
(63) . Accumulation of TAG in these tissues, by some unknown mechanism, 
but probably involving local TAG hydrolysis and availability of fatty acids or 
fatty acyl-CoA, leads to an impairment of the normal sensitivity of glucose 
metabolism to insulin (or, in the case of the â-cell, to an impairment of insulin 
secretion in response to glucose) (63).  
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2.3  Thyroid stimulating hormone (TSH) 
2.3.1  TSH overview 
TSH is glycoprotein hormone produced in the thyrotrophs of the anterior 
pituitary gland. Its synthesis and secretion are stimulated by thyrotropin  
releasing hormone( TRH) and inhibited by thyroid hormone in a classic 
endocrine negative feedback loop (64).  
 
2.3.2 TSH Structure 
 Human TSH consists of two noncovalently linked subunits, -subunit 
(92 amino cids; common for other human glycoprotein hormones) and TSH -
subunit. The primary structures of TSH subunits are species specific. Human 
TSH, for example, differs from bovine TSH by 28 amino acids in the -subunit 
and by 12 amino acids in the  -subunit. The coding sequence of the TSH -
subunit gene predicts a 118-amino acid protein (65). However, -subunit of 
TSH isolated from cadaver pituitary is composed of 112 amino acids (66), 
most likely due to proteolytic cleavage during purification (67). TSH, similar to 
other glycoprotein hormones, is a glycosylated protein. The carbohydrate 
chains constitute 15-25% of its weight and include three asparagine  linked 
carbohydrate chains (68). 
 
2.3.3  TSH  function and physiological role  
TSH controls thyroid function upon its interaction with the G protein-coupled 
TSH receptor (69,70 ,71,72). TSH binding to its receptor on thyroid cells leads 
to the stimulation of second messenger pathways involving predominantly 
cyclic adenosine monophosphate (cAMP) and, in high concentrations, inositol 
1,4,5-triphosphate and diacylglycerol, ultimately resulting in the modulation of 
thyroidal gene expression (73). 
 Physiological roles of TSH include the stimulation of differentiated thyroid 
functions, such as iodine uptake and organification, the release of thyroid 
hormone from the gland, and promotion of thyroid growth (65). It also acts as 
a thyrocyte survival factor and protects the cells from apoptosis (74), via 
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regulation of p53 and the bcl-2 gene family (75,76). A further interesting 
finding is that TSH plays a critical role in ontogeny (77).  
2.4   Thyroid gland and hormone secretion  
2.4.1   Definition 
The thyroid gland is a bilobed organ of endocrine system located in the neck 
region. The gland produces thyroid hormones and calcitonin in two distinct cell 
types, the thyroid follicular cells (TFCS) and the parafollicular or C cells, 
respectively. The TFCs, the most numerous cell population in the gland, form 
the thyroid follicles, spherical structures serving as storage and controlled 
release of thyroid hormones (78). 
 
2.4.2  Thyroid hormones 
Thyroid hormones (THs) play critical roles in differentiation, growth, and 
metabolism. Indeed, TH is required for the normal function of nearly all tissues, 
with major effects on oxygen consumption and metabolic rate (79). Disorders of 
the thyroid gland are among the most common endocrine maladies. 
Furthermore, endemic cretinism due to iodine deficiency remains a public health 
problem in developing countries. TH synthesis and secretion is exquisitely 
regulated by a negative-feedback system that involves the hypothalamus, 
pituitary, and thyroid gland (hypothalamic/pituitary/thyroid (HPT) axis)(80). 
THs, T4 and the more potent T3, are synthesized in the thyroid gland.  Iodide is 
actively transported and concentrated into the thyroid by Na+/I  symporter (NIS 
)(81,82). The trapped iodide is oxidized by thyroid peroxidase (TPO) in the 
presence of hydrogen peroxide and incorporated into the tyrosine residues of a 
glycoprotein, thyroglobulin (Tg). This iodination of specific tyrosines located on 
Tg yields monoiodinated and diiodinated residues (MIT, monoiodo-tyrosines; 
DIT, diiodo-tyrosines) that are enzymatically coupled to form T4 and T3. The 
iodinated Tg containing MIT, DIT, T4, and T3, then is stored as an extracellular
 
storage polypeptide in the colloid within the lumen of thyroid follicular cells. 
Genetic defects along the synthetic pathway of THs have been described in 
humans and are major causes of congenital hypothyroidism in iodine-replete 
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environments (83,84). The majority of released TH is in the form of T4, as total 
serum T4 is 40-fold higher than serum T3. Only 0.03% of
 the total serum T4 is 
free (unbound), with the remainder bound to carrier proteins such as thyroxine 
binding globulin (TBG), albumin, and thyroid binding prealbumin. Approximately 
0.3% of the total serum T3 is free, with the remainder bound to TBG and
 
albumin. It is the free TH that enters target cells and generates a biological 
response. 
The major pathway for the production of T3 is via 5'-deiodination of the outer 
ring of T4 by deiodinases and accounts for
 the majority of the circulating T3 
(85,86). Type I deioidinase is found in peripheral tissues such as liver and 
kidney and is responsible for the conversion of the majority of T4 to T3 in
 
circulation. Type II deiodinase is found in brain, pituitary, and brown adipose 
tissue and primarily converts T4 to T3 for intracellular
 use (87). 5'-Deiodination 
by type I deiodinase and type III deioidinase, which is found primarily in 
placenta, brain, and skin, leads to the generation of reverse T3 (rT3), the key 
step in the inactivation of TH. rT3 and T3 can be further deiodinated
 in the liver 
and are sulfo- and glucuronide-conjugated before excretion in the bile (88).                   
 
2.4.3  Thyroid hormone receptors 
Thyroid receptors (TRs ) have been shown to belong to a large superfamily of 
nuclear hormone receptors that include the steroid hormones (89,90). 
Although THs may exert their effects on a number of intracellular loci, their 
primary effect is on the transcriptional regulation of target genes. Early studies 
showed that the effects of THs at the genomic level are mediated by nuclear 
TRs, which are intimately associated with chromatin and bind TH with high 
affinity and specificity (79,91). Similar to steroid hormones that also bind to 
nuclear receptors, TH enters the cell and proceeds to the nucleus. It then 
binds to TRs, which may already be prebound to thyroid receptor elements 
(TREs) located in promoter regions of target genes. The formation of ligand-
bound TR complexes that are also bound to TREs is the critical first step in 
the positive or negative regulation of target genes and the subsequent 
regulation of protein synthesis (92). TRs share a similar domain organization 
with other family members as they have a central DNA-binding domain 
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containing two "zinc fingers" and a carboxy-terminal ligand binding domain 
( LBD). Initial studies suggested that there were multiple TR isoforms,and 
subsequent work has confirmed that there are two major TR isoforms encoded 
on separate genes, designated as TR  and TR , encoded on human 
chromosomes 17 and 3, respectively. Moreover, these multiple isoforms exist 
in different species such as amphibians, chick, mouse, rat, and human (93). 
Both TR isoforms bind T3
  and mediate TH-regulated gene expression (94, 
95,96).  
 
2.4.4  Nongenomic effects of thyroid hormones  
There is general agreement that most of the effects of T3 are mediated by TR 
regulation of target gene transcription in the nucleus. However, there are a 
number of reports on nongenomic effects by T3 and T4 (97). Evidence for 
these nongenomic effects include the lack of dependence on nuclear TRs and 
structure-function relationships of TH analogs that are different from their 
affinities for TRs. There also can be rapid onset of action (typically seconds to 
minutes), and utilization of membrane-signaling pathways, typically involving 
kinases or calmodulin, that have not been implicated in direct TR function. The 
putative nongenomic effects by TH are diverse (92).  
 
2.4.5  Thyroid hormone effects on target tissues 
TRs are expressed in virtually all tissues, although the relative expression of 
TR isoforms may vary among tissues (98, 99,100). In addition to this variable 
expression of TR isoforms in different tissues, the role of TH can vary in 
different tissues. Indeed, the myriad effects by a single hormone on so many 
different tissues is surprising and underscores TH's vital role in cellular 
function (92) . Thus, in addition to its role on the metabolism of macronutrients 
and overall energy and oxygen consumption,TH also regulates important 
functions in specific tissues such as: 
1- Bone : TH is critical for normal bone growth and development. In children, 
hypothyroidism can cause short stature and delayed closure of the epiphyses. 
Biochemical studies have shown that TH can affect the expression of various 
bone markers in serum, reflecting changes in both bone formation and 
 
resorption (101, 102,103). TH increases alkaline phosphatase and osteocalcin 
in osteoblasts. TH may act on bone via TH stimulation of growth hormone and 
insulin-like growth factor I (IGF-I) or by direct effects on target genes 
(102,104). 
2- Heart : TH lowers systemic vascular resistance, increases blood volume, 
and has inotropic and chronotropic effects on cardiac function (105). The 
combination of these effects on both the circulation and the heart itself results 
in increased cardiac output. Hyperthyroid patients have a high output 
circulation state, whereas hypothyroid patients have low cardiac output, 
decreased stroke volume, decreased vascular volume, and increased 
systemic vascular resistance (105). These changes in cardiac function by TH 
ultimately depend on the regulation of target genes within the heart and 
indirect effects due to hemodynamic changes by TH. TH enhances overall 
total protein synthesis in the heart (106,107). Additionally, it regulates the 
transcription of several specific proteins that are critical for cardiac function 
such as myosin heavy chain (MHC) genes (106). 
3- Liver : TH has multiple effects on liver function including the stimulation of 
enzymes regulating lipogenesis and lipolysis as well as oxidative processes 
(79,108). Some of the lipogenic enzymes that are regulated are malic enzyme, 
glucose-6-phosphate dehydrogenase, and fatty acid synthase (109). It has 
been appreciated for many years that hypothyroidism is associated with 
hypercholesterolemia with elevated serum intermediate and low-density 
lipoprotein (LDL) cholesterol concentrations (110). The major mechanism for 
these effects may be lower cholesterol clearance resulting from decreased 
LDL receptors. An additional mechanism may be decreased hepatic lipase 
activity in hypothyroidism which decreases conversion of intermediate-density 
lipoproteins to LDL and high-density lipoprotein metabolism (111,112). 
4- Pituitary : TH regulates the synthesis and secretion of several pituitary 
hormones (113).TH also can negatively regulate thyrotropin (TSH) 
transcription by direct and indirect mechanisms(114). TH can negatively 
regulate thyrotropin releasing hormone (TRH) at the transcriptional level, 
which in turn decreases transcription of TSH mRNA (115,116). TH also can 
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negatively regulate TSH by decreasing transcription of the glycoprotein 
hormone -subunit (common to TSH, luteinizing hormone, follicle-stimulating 
hormone, and human chorionogonadotropic hormone) (114,117 -122). 
5- Brain : TH has major effects on the developing brain in utero and during 
the neonatal period (123,124). Neonatal hypothyroidism due to genetic causes 
and iodine deficiency in humans can cause mental retardation and 
neurological defects (125,126).  
2.4.6  Thyroid and lipid metabolism 
The role of thyroid hormone in the regulation of lipid metabolism has been of 
interest ever since a relationship  between thyroidal state and body weight 
was identified (127) .The relationship between body fat, thyroidal state, and 
metabolism became firmly established with the measurement of basal 
metabolic rates (128). These studies clearly showed that hyperthyroidism is 
associated with an increase in metabolic rate (oxygen consumption) and that 
hypothyroidism is associated with a decrease in metabolic rate. Moreover, the 
changes in metabolic rate were associated with alterations in lipid and 
carbohydrate metabolism (129).  However, the mechanisms leading to these 
changes are complex because alterations in thyroidal state affect multiple 
systems and multiple target tissues. 
 Thyroid hormone regulates the rate of both fat synthesis (lipogenesis) and 
lipolysis (130). T3 induces key lipogenic enzymes
 such as acetyl CoA 
carboxylase, malic enzyme, glucose-6-phosphate dehydrogenase and fatty 
acid synthase (131, 132, 133, 134,135). The expression of these genes is also 
modulated by other factors such as high-carbohydrate diet, insulin, and CAMP 
(79,136). Researchers demonstrated that the enzymes in the lipogenic 
pathway are regulated by thyroid  hormone in both the liver and adipose 
tissue (137) Moreover, they showed that thyroid hormone and dietary sucrose 
act synergistically to control the content of these enzymes (138). With the 
advent of newer technology, some of the controversial issues discussed 
above will be answered. In this issue researchers make use of a new 
microdialysis technique to study the effect of thyroidal state on lipolysis in vivo. 
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They measured local release of norepinephrine (NE) and showed that (NE) 
concentrations at the adipocyte are greater in hyperthyroid patients and 
significantly less in hypothyroid patients compared with euthyroid controls 
(139). 
2.4.7 Increased oxidative energy metabolism 
Thyroid hormone has long been recognized as a major regulator of the 
oxidative metabolism of energy producing substrates by the mitochondria. 
The mitochondria are often called the "cell's powerhouses" because this is 
where foodstuffs are turned into useful energy in the form of ATP (140). T3 
and diiodotyrosine(T2) increase the flux of nutrients into the mitochondria as 
well as the rate at which they are oxidized, by increasing the activities of the 
enzymes involved in the oxidative metabolic pathway. The increased rate of 
oxidation is reflected by an increase in oxygen consumption by the body.T3 
and T2 appear to act by different mechanisms to produce different results. T2 
is believed to act on the mitochondria directly, increasing the rate of 
mitochondrial respiration, with a consequent increase in ATP production. T3 
on the other hand acts at the nuclear level, inducing the transcription of genes 
controlling energy metabolism, primarily the genes for so-called uncoupling 
proteins, (UCP). 
 
 The time course of these two actions is quite different. T2 begins to increase 
mitochondrial respiration and metabolic rate immediately. T3 on the other 
hand requires a day or longer to increase BMR since the synthesis of new 
proteins, the UCP, is required (140). There are a number of putative 
mechanisms whereby T2 is believed to increase mitochondrial energy 
production rates, resulting in increased ATP levels. These include an 
increased influx of Ca++ into the mitochondria, with a resulting increase in 
mitochondrial dehydrogenases. This in turn would lead to an increase in 
reduced substrates available for oxidation. An increase in cytochrome oxidase 
activity has also been observed (141).  
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2.4.8  Mitochondrial uncoupling 
 The mitochondria are often characterized as the cell's powerhouse. They 
convert foodstuffs into ATP, which is used to fuel all the body's metabolic 
processes. Much research suggests that T3 has the ability to uncouple 
oxidation of substrates from ATP production. T3 is believed to increase the 
production of so called uncoupling proteins. Uncoupling protein (UCP) is a 
transporter family that is present in the mitochondrial inner membrane, and as 
its name suggests, it uncouples respiration from ATP synthesis by dissipating 
the transmembrane proton gradient as heat. Instead of useful ATP being 
produced from energy substrates, heat is generated instead ().  
 
2.4.9 Adrenergic receptor  modulation                                      
Administration  of  T3  has  been shown  to  upregulate  the  so - called â 2 
adrenergic receptor in fat tissue. What is the significance of this effect for fat 
loss?  Before fat  can be used  as fuel,  it must be mobilized from the fat cells  
where it is stored. An enzyme called  hormone  sensitive lipase (HSL) is  the 
rate - controlling enzyme in lipolysis, or  fat mobilization.  The body produces 
two  catecholamines,  epinephrine  and nor epinephrine,  which  bind  to the 
beta 2 receptor and  activate HSL. The upregulation of the â 2 receptor  due  
to  T3 results in an increased  ability of catecholamines to activate HSL, 
leading to increased lipolysis () . 
 
2.4.10  Decreased phosphodiesterase expression 
In hyperthyroid patients as well as in normal subjects given T3, levels of the 
enzyme phosphodiesterase are lowered in fat cells (). When lipolytic 
hormones like epinephrine bind to the beta 2 receptor described above, they 
initiate a signaling cascade mediated by the so called (secend messenger) 
cyclic AMP (cAMP). cAMP in turn acts on other cellular enzymes to initiate 
and maintain lipolysis. The original signal is terminated when cAMP is 
degraded by the enzyme phosphodiesterase. Maintaining elevated cAMP 
levels, by lowering phosphodiesterase concentrations with T3, will prolong 
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                     3. Materials and methods 
3.1 Study design   
The present study is a case  control.  
 
3.2 Study population  
The study population comprised  two groups, the cases (individuals with BMI 
>30 kg/m2), and the controls (non-obese individuals with BMI18.5-24.9 kg/m2).  
Cases and controls reside in Gaza Governorate and aged matched  (20-40) 
years.  
 
3.3. Sampling and sample size 
Eighty two obese individuals were selected from Gaza governorate and 
another 82 of normal weight individuals who have the same conditions were 
selected as a control group. The sample size calculations were based on the 
formula for case-control studies. EPI-INFO statistical package version 3.5.1 
was used with 95% CI, 80% power and 50% proportion as conservative and 
OR>2. The sample size in case of 1:1 ratio of case control was found to be 
73:73. For a no-response expectation, the sample size was increased to 82 
obese individuals and the controls also consisted of 82 normal weight 
individuals. 
3.4  Inclusion criteria 
A. Case group 
1. Men aged 20-40 years old.  
2. (BMI) over 30kg/m2. 
3. Non diabetic normotensive  individuals. 
B- Control group 
The inclusion criteria for control group are similar to the case group except 
that they are normal weight. 
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3.5 Questionnaire  
A meeting interview was used for filling in the questionnaire for both cases 
and controls (Appeddixe1). All interviews were conducted face to face by the 
researcher himself. During the survey the interviewer explained any of the 
questions that were not clear. Most questions were yes/no question, which 
offer a dichotomous choice, and the multiple choice questions. The questions 
were direct and brief and the validity of the questionnaire was tested by three 
specialists. The questionnaire included personal information, various obesity 
related items, thyroid disorders, eating habits and physical activity.  
 
3.6 Pilot study 
Pilot study was done prior to beginning real data collection to know the length 
and clarity of questionnaire and to evaluate the outcome. Ten individuals were 
interviewed. At the end of the pilot study, a comprehensive revision to 
questionnaire was made and modified as necessary. The pilot subjects were 
not included in the study. 
 
3.7 Ethical consideration  
An approval to carry out the study was obtained from the Helsinki Committee-
Gaza (Appeddixe2). Cases and controls participation was voluntary in the 
study and all information  obtained were kept as confidential.  
 
3.8 Body mass index (BMI) 
BMI was used for the evaluation of the obesity. To measure BMI, we  weighed 
the individuals in underclothes and without  shoes. Height was measured 
without shoes. Medical balance (Detecto scale), was used for this 
purpose. Body mass index is a statistical measurement which compares a 
person's weight and height, which can be used to indicate if individuals are 




            Weight in Kilograms              
             (Height in Meters)2  
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BMI Categories: 
 Underweight = < (18.5) kg/m2 
 Normal weight = (18.5-24.9) kg/m2 
 Overweight = (25-29.9) kg/m2 
 Obesity = BMI of (30) kg/m2 or greater 
 
3.9 Blood sample collection 
Twelve hours fast blood samples were collected from the cases and controls. 
About 5 ml of venous blood was drawn from each individual. The serum 
samples were rapidly separated by centrifugation for 10 minute at room 
temperature at 3500 rpm, the separated samples were frozen at -20 C until 
assay. 
 
3.10 Biochemical analysis 
3.10.1 Determination of insulin 
Monobinds insulin MAPS ELISA test kit (Insulin-C peptide/ Product code 




The essential reagents required for an immunoenzymometric assay include 
high affinity and specificity antibodies (Ab) (enzyme conjugated and 
immobilized), with different and distinct epitope recognition, in excess, and 
native antigen (Ag). In this procedure the immobilization takes place during 
the assay at the surface of the microplate well through the interaction of 
streptavidin coated on the well and exogenously added biotinylated  
monoclonal insulin antibody. Upon mixing monoclonal biotinylated antibody, 
the enzyme labeled antibody and a serum containing the native antigen 
reaction results between the native antigen  and the antibodies without 
competition or steric hindrance, to form soluble sandwich complex. 
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Simultaneously  the complex is deposited to the well through the high affinity 
reaction of streptavidin and biotinylateed antibody, after equilibrium is attained 
the antibodybound fraction is separated from unbound antigen by 
decantation or aspiration. The enzyme activity in the antibody-bound fraction 
is directly proportional  to the native antigen concentration . 
 
- Reagents  
A. Insulin calibrators-2ml/vial(dried),Six (6) vials of references for insulin 
antigens at levels of 0(A),5(B),25(C),50(D),100(E),and 300(F) (ìIU/ml). each 
vial was reconstituted with 2 ml of distilled water. 
 B. Insulin enzyme reagent (13ml/vial ), One (1) vial  containing enzyme 
labeled affinity purified monoclonal mouse x-insulin IgG, Biotinylatrd  
monoclonal mouse x-insulin IgG in buffer, dye, and preservative .  
C. Streptavidin coated plate (96wells), One 96 well microplate coated  with 
streptavidin  and packaged in an aluminum bag with a drying agent.  
D. Wash solution concentrate (20 ml), One (1) vial containing a surfactant in 
phosphate buffered saline, a preservative has been added.  
E. Substrate A (7ml/vial), One bottle containing tetramethylbenzidine (TMB) in 
buffer  store at 2-8c 
F. Substrate B (7ml/vial), One bottle containing hydrogen peroxide (H2O2) in 
buffer. 
G. Stop solution (8ml /vial), One bottle containing  a strong acid  (1N HCL). 
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- Reagent preparation  
1. Wash buffer, contents of wash solution were diluted to 1000ml with distilled 
water  in a suitable storage container.  
2. Working substrate solution, the contents of the amber vial labeled solution 
A were added into the clear vial labeled solution B. mixed and labeled 
accordingly. 
- Assay  procedure 
Before proceeding with  the assay all reagents, serum, references and 
controls were brought to room temperature. 
1. Microplates wells for calibrator, control and patient specimen were assayed 
in duplicate. 
2. 50 ìl of the appropriate calibrators, controls and samples were pipeted  into 
the assigned wells. 
3. 100 ìl of the insulin enzyme reagent were added to each well. 
4. The microplate was swirled gently for 20-30 seconds in order to mix and 
covered with plastic wrap. 
5. The microplate was Incubated for 120 minutes at room temperature. 
6. The contents of the microplate were discarded  by decantation or 
aspiration.  
7. 300 ìl of wash buffer were added, decant or aspirate. An automatic washer 
was used. 
8. 100  ìl of  working substrate solution were added to all wells. 
9. The microplate was Incubated at room temperature for 15 minutes. 
10. 50 ìl of stop solution were added to all wells and mixed gently for 15-20 
seconds. 
 
11. The absorbance was measured at 450 nm  in a microplate ELISA reader.  
- Insulin normal range  
children < 12 < 10 ìIU/ml 
adult normal 0.7-9 ìIU/ml 
Diabetic (type2) 0.7-25  ìIU/ml 
 
3.10.2 Determination of thyroid stimulating hormone  (TSH) 
The Teco Thyroid Stimulating Hormone ELISA test kit was used for the 
quantitative determination of thyroid stimulating hormone (TSH) concentration 
in serum. 
 
- Principle  
The essential reagents required for an immunoenzymometric assay include 
excess amount of antibodies (both enzyme conjugated and immobilized) with 
high affinity, high specificity and contain different epitopes with distinct 
recognition and native antigen. In this assay procedure, the immobilization 
takes place at the surface of a microplate well through the interaction of 
streptavidin coated on the well and exogenously added biotinylated 
monoclonal anti-TSH antibody. Upon mixing, a reaction results between the 
native antigen contained in serum, the monoclonal biotinylated antibody and 
the enzyme-labeled antibody, without competition or steric hindrance, to form 
a soluble sandwich complex. Simultaneously, the complex is deposited to the 
well through the high affinity reaction of streptavidin and biotinylated antibody. 
After equilibrium is attained, the antibody-bound fraction is separated from 
unbound antigen by decantation or aspiration. The enzyme activity in the 
antibody-bound fraction is directly proportional to the native antigen 
concentration.  
 
- Reagents  
1. Streptavidin coated microplate: containing 96 wells per kit 
2. Enzyme Conjugate: containing TSH antibody conjugated with HRP and 
biotinylated antibody in buffer, 13 ml. 
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3. TSH Reference Standard set: (7 1-mL vials) containing 0, 0.5, 2.5, 5.0, 10, 
20 and 40 ìIU/ml TSH antigen in buffer. Exact concentrations are given on 
the package labels on a lot specific basis. 
4. TMB Solution: containing TMB and H2O2 reagent in amber 
bottle, 11 ml. 
5. Stop Solution: containing diluted hydrochloric acid, 8 ml. 
6. Wash Solution concentrate: 20 ml. 
 
  Reagent preparation 
1.  All reagents were allowed to reach room temperature before use. 
 
2. Working wash solution: 20 mL of wash solution concentrate were added to 
1000 mL of deionized water, and mixed well.  
 
- Assay procedure 
1. The desired number of coated wells were secured  in the holder.  
2. 50  ìl of standards, sample and controls were pipetted  into each well. 
3. 100 ìl of conjugate reagent were pipetted into each well, and  mixed 
thoroughly for 30 seconds. 
4. The microplate was incubated at room temperature for 60 minutes. 
5. The contents of the wells were discarded by decantation or aspiration.  
6. 300 ìl of working wash solution were pipetted. An automatic ELISA washer 
was used.  
7. One hundred  ìl of TMB reagent were added into each well, and gently 
mixed for 10 seconds. 
9. The microplate was Incubated at room temperature in the dark for 15 
minutes without shaking. 
10. 50 ìl of stop solution were pipetted to each well and gently mixed for 10-20    
seconds. It is critical to make sure that the blue color was changed to yellow                             
color completely. 






    -  Expected values  
 
Expected values 0.4  6.0 ìIU/ml 
 
 
3.10.3  Determination of Glucose  
Serum glucose was determined by enzymatic colorimetric method for the 




Glucose is transformed by glucose oxidase (GOD) into gluconic acid and 
hydrogen peroxide, which in presence of peroxidase (POD), reacts with 
phenol and 4-aminoantipirine to form a red complex, whose intensity at 510 
nm is proportional to the glucose concentration in the sample. 
                                             
Glucose + O2 + H2O                     Gluconic acid + H2O2 
                                                                   
H2O2 + Phenol + 4-Aminoantipirine                       Red complex + H2O 
 
- Reagents 
- Reagent A 
Phosphate buffer pH  (7.4)                                25 g/l 
Phenol < 0.9 g/l 
4-Aminoantipirine                                       0.4 mmol/l 
GOD    ≥ 30 kU/l 
POD   ≥ 1 kU/l 





          D-Glucose                                              100 mg/dl (5.55mmol/l) 







Assay  procedure 
About 0.5 ml  of serum was transferred to the  Mindray  BS-120 chemistry  
autoanalyzer to perform the test  according to these parameters : 
Parameter Value 
Reagent  (ìI) 300 
     Serum    (ìI) 3 
Incubation period (s) 17×18 
Reaction type End point 
Wavelength (nm) 510 
 
 
 - Reference values 
Adults 70-115 mg/dl 
Newborn 20-80 mg/dl 
Children<5 Years values 10-15% lower of adults ones 
 
 
3.10.4 Determination of total cholesterol  
Total Cholesterol was determined by enzymatic colorimetric method for the 
quantitative determination of total cholesterol in serum or plasma, using Globe 
diagnostics kit, (Italy). 
 
Principle      
The measurement is based on the following enzymatic reactions: 
                                               
Cholesterol esters + H2O                     Cholesterol + Fatty acids 
                          
Cholesterol + O2                       Cholest-4-en-3-one + H2O2 
                                                                              
2 H2O2 + hydroxybenzoate + 4-Amminoantipyrine             Red complex + 4H20 
 
The intensity of the red complex is proportional to the total cholesterol present 
in the sample. 
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- Reagents 
- Reagent A 
 
Good buffer, pH (6.7)                                              50 mmol/l
Cholesterol oxidase (CHOD)                                  ≥ 100 U/l 
Cholesterol esterase (CHE)                                      ≥ 300 U/l
Hydroxybenzoic acid                                            12 mmol/l
4-Amminoantipirine                                               0.3 mmol/l 
Peroxidase (POD)                                                  ≥ 500 U/l




         Cholesterol     200 mg/dl 
 
 
Assay  procedure  
About 0.5 ml  of serum was transferred to the Mindray  BS-120 chemistry 
autoanalyzer to perform the test  according to these parameters : 
Parameter Value 
Reagent  (ìI) 300 
Serum      (ìI) 3 
Incubation period (s) 17×18 
Reaction type End point 
Wavelength (nm) 510 
 
Reference range 
Cholesterol values according to a study on a population of adults in absence 
of coronary disease are the following : 
 
Recommended values < 200 mg/dl 
Upper limit 200  239 mg/dl 







3.10.5 Determination of triacylglycerol 
Triacylglycerol were determined by enzymatic colorimetric method, for the 
quantitative determination of Triacylglycerol in serum, plasma using Globe 
diagnostics kit ,(Italy). 
 
Principle   
Glycerol, released from triglycerides after hydrolysis with lipoproteinlipase is 
ransformed by glycerolkinase into glycerol-3-phosphate which is oxidized by 
glycerolphosphate oxidase into dihydroxyacetone phosphate and hydrogen 
peroxide. In presence of peroxidase, the hydrogen peroxide oxidizes the 
chromogenESPT (4-aminophenazone/N-ethylmethylanilin- propan-sulphonate 
sodic) to form purple quinoneimine whose colour intensity, measured at 510 
nm, is proportional to the concentration of triglycerides in the sample. 
         
     
Triacylglycerol                 Glycerol + Fatty acids 
                           
Glycerol + ATP                 Glycerol-3-phosphate + ADP 
                                          
Glycerol-3-phosphate + O2                   Dihydroxyacetone phosphate + H2O2 
                                                             





- Reagent A 
 
Good Buffer pH  (7.2) 50 mmol/l 
ESPT 4 mmol/l 
ATP 2 mmol/l 
Mg++ 2 mmol/l 
Lipoproteinlipase (LPL) >1 kU/l 
Glycerol kinase (GK) > 0.4 kU/l 
Glycerolphosphate oxidase (GPO) >1.5 kU/l 
4-Amminoantipirine 0.5 mmol/l 
Peroxidase (POD) >1 kU/l 
NaN3 < 0.095 g/l 
 
- Standard 
                 Glycerol     200 mg/dl 
                  NaN3 ≤0.095g/l  
 
Assay  procedure  
About 0.5 ml  of serum was transferred to the Mindray  BS-120 chemistry 
autoanalyzer to perform the test  according to these parameters : 
Parameter Value 
Reagent  (ìI) 300 
Serum      (ìI) 3 
Incubation period (s) 17×18 
Reaction type End point 
Wavelength (nm) 510 
 
Reference range 
Recommended values < 200 mg/dL 
Upper limit 200-400 mg/dl 
High values > 400 mg/dl 
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3.10.6 Determination of high density lipoprotein cholesterol 
(HDL-c)   
HDL cholesterol was determined by liquid HDL precipitant for the 
determination of HDL cholesterol using Globe diagnostics kit, Italy. 
- Reagents 
- Precipitating Reagent 
 
PEG 6000                                                      14.5%
Surfactants and preservative 
 
 
- Assay  procedure 
1- 0.5 ml serum and 0.5 ml precipitating reagent were pipetted into conic test 
tubes. 
2. Then mixed gently by inversion, and wait 5 minutes and centrifuged at 
(3000 rpm ) for 20 minutes. 
3. The supernatant was removed for the HDL cholesterol determination as 
follows: 
- About 0.5 ml  of supernatant was transferred to the Mindray BS-120 
chemistry autoanalyzer to perform the test  according to these parameters:  
Parameter Value 
 Reagent  (ìI) 200 
supernatant  (ìI) 3 
Incubation period (s) 17×18 
Reaction type End point 
Wavelength (nm) 510 
 
- Reference value 








<  40 mg/dl                  40  59 mg/dl > 60 mg/dl 
 
 
3.10.7 Determination of Low density lipoprotein  cholesterol 
(LDL- c) 
LDL-c was calculated from the primary measurements using the empirical 
equation  
LDL-c (mg/dl) = total cholesterol  triglyceride/5  HDL-c 
 
3.11 Statistical analysis 
Data obtained was arranged and entered to computer to be statistically 
analyzed  using Statistical Package for the Social Sciences (SPSS) program 
(version 18) . Data analysis was carried out as follows : 
1. Data cleaning 
2. Frequency table for all the study variables. 
3. Defining and recording of certain variables. 
4. Cross tabulation and advanced statistical analysis. 
 
The following tests were applied  
1. ANOVA test 
2. Chi-square test  
3. T- test 
4. Spearman correlation coefficient 
5. Graphs were plotted 






Mean of cases  mean of controls              
























4.1 Questionnaire data 
4.1.1 General description of the study population  
The study population comprised 82 obese individuals (case group), and 82  
control individuals. Table 4.1 shows the general characteristics of the study 
population. The age of the study population ranged from 20-40 years with 
mean of (27.1±5.2) years for controls and (27.4 ±5.6) years for cases. Fifty 
one (62.1%) and 29 (35.4%) of controls and cases were single whereas 
31(37.9%) and 53 (64.6%) were married. Analysis of the educational status 
showed that 3 (3.6%) controls and 4 (4.9%) cases were illiterate, 10 (12.4%) 
and 14 (17.0%) had passed primary school,19 (23.1%) and 17 (21.0%) had 
finished preparatory school, 23 (28.0%) and 19 (23.1%) had finished 
secondary school and 27 (32.9%) and 28 (34.0%) had a university degree. A 
total of 47 (57.3%) controls and 51 (62.2) cases were employed whereas 35 
(42.7%) and 31 (37.8%) were unemployed. In addition, 22 (26.8%) controls 
and 20 (24.4%) cases were smokers. 
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4.1.2 Various obesity related items as reported by the study 
population 
Table 4.2 provides various obesity related items as reported by the study 
population. A total number of 14 (17.1%) cases had history of hyperlipidemia  
compared to only one control (1.2%). The difference was significant with 2 
=10.566 and p=0.001. The number of cases who reported suddenly weight 
gain 38 (46.3%) or trying to lose weight but failed 19 (23.2%) were 
significantly higher than controls 2 (2.4%) and 0 (0.0%), respectively (2 
=40.504, p=0.000 and 2 =19.287, p=0.000). Seventy (85.4%) cases indicated 
obesity among their first degree relatives in comparison to 30 (36.6%) controls 
who did (2 =41.0, p=0.000) indicating that family history is a risk factor for 
obesity.   
 





































































































* p value of 2 (corrected) test 
 
 
4.1.3 Thyroid disorders  
Table 4.3 summarizes thyroid disorders among the study population. The 
controls and cases who reported getting fatigue quickly were  8 (9.8%) and 37 
(45.1%) respectively compared to 74 (90.2%) and 45 (54.9%) who did not get 
fatigue (2 =25.756, p=0.000). Muscle weakness was higher in cases; 15 
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(18.3%) than in controls; 4 (4.9%) with 2 =5.953 and p=0.015. In addition, 
consumption of suitable quantities of marine food was lower in cases; 19 
(23.2%) compared to controls; 34 (41.5) with 2 =6.272 and p=0.012. This 
indicates that previous factors are more likely to be associated with obesity. 
The remaining disorders including decreased sweating, slow heart rate, 
difficulty in concentrating or remembering things, sleep problems and feeling 
lazy when waking up showed no significant differences between cases and 
controls (p>0.05).      
 






















































































































Consumption of suitable 






























































































* Non applicable 
** p value of 2 (corrected) test 
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4.1.4 Eating habits among  the study population 
Table 4.4 illustrates eating habits among  the study population. A total number 
of 44 (53.7%) cases mentioned that they eat large quantities of carbohydrate 
and lipid in comparison to their counterparts of 28 (34.1%). The difference 
between the two groups was significant (2 =6.338 and p=0.012) implying that 
eating large quantities of  carbohydrate and lipid are associated with obesity. 
However, no significant differences were observed between cases and 
controls for eating just before bed time and snacking between meals (2 
=3.310, p=0.069 and 2 =0.098, p=0.754, respectively). 
 
 















Eating large quantities of  




































































4.1.5 Physical activity among the study population 
The Physical activity among the study population is illustrated in Table 4.5. 
The number of cases who had regular exercise 9 (11.0%), walking regularly 
18 (22.0%) and having active job 22 (26.8%), were less than their 
counterparts of controls 15 (18.3%), 45 (54.9%) and 36 (43.9%), respectively. 
However, the difference was significant for walking regularly and having active 





















































































4.2 Biochemical parameters of the study population 
4.2.1 Insulin, glucose and thyroid stimulating hormone  
Table 4.6 shows the levels of Insulin, glucose and thyroid stimulating hormone 
(TSH) in controls and cases. The mean levels of insulin and glucose were 
significantly increased among cases compared to controls (mean=13.0±13.0 
and 91.0±20.2 Vs 6.9±8.0 and 83.7±11.2, % difference=88.4 and 8.7, 
P=0.000 and 0.005, respectively). In contrast, the mean levels of TSH were 
lower in cases compared to controls (mean=1.41±1.23 Vs 1.93±0.98, % 
difference=26.9 and P=0.003. 
 































-26.9 -2.983 0.003 
TSH*: Thyroid stimulating hormone.  





4.2.2 lipid profile of the study population 
Lipid profile including, total cholesterol, triacylglycerol, high density 
lipoproteins (HDL) and low density lipoproteins (LDL) are listed in Table 4.7. 
The mean levels of total cholesterol, triacylglycerol and LDL increased in 
cases compared to controls (mean=187.3±38.5mg/dl,139.2±63.7mg/dl and 
119.4±34.8mg/dl Vs 174.9±43.5mg/dl, 98.9±68.6mg/dl and 107.9±42.4mg/dl, 
% difference=7.1, 40.7 and 10.6, respectively). However, the difference was 
significant only for triacylglycerol (P=0.000). In contrast, the mean level of 
HDL was significantly decreased in cases compared to controls 
(40.1±10.9mg/dl Vs 47.7±9.6mg/dl, % difference=15.9 and P=0.000)  
 

























40.7 3.900 0.000 






-15.9 -4.723 0.000 






10.6 1.911 0.058 
HDL*: High density lipoprotein, LDL**: Low density lipoprotein. 
All values are expressed as mean ±SD. 











4.3 Distribution of different grades of body mass index 
(BMI) among cases 
Table 4.8 illustrates the distribution of different grades of body mass index 
(BMI) among cases (obese individuals). Twenty seven (32.9%) of cases were 
found to be obese grade 1, 27 (32.9%) were obese grade 2 and 28 (34.2%) 
were obese grade 3.   
 
 
Table 4.8. Distribution of different grades of body mass index (BMI) 
among cases 
 




Grade 1 (30-34.9) 27 32.9 
Grade 2 (35-39.9) 27 32.9 
Grade 3 ( ≥ 40)      28 34.2 
 
Weight classifications by BMI: people with BMI=(30-34.9) were considered obese grade I 
and those with BMI=(35-39.9) were obese grade II, and people with BMI=≥40 were 
classified as morbid obese of grade III (47). 
 
4.4 Body mass index in relation to different  biochemical 
parameters of cases 
Table 4.9 presents the relation between (BMI) and the studied biochemical 
parameters including insulin, TSH, glucose, total cholesterol, triacylglycerol, 
HDL and LDL of cases. There was no significant relation between these 










Table 4.9. Categories of body mass index in relation to different 
biochemical parameters of cases. 




















15.2±21 11.9±7.6 12.1±4.3 0.546 0.432 
TSH* 
(ìIU/mL) 
1.4±1.4 1.4±1 1.5±1.5 0.054 0.947 
Glucose 
(mg/dl) 
90.7±25.6 95.2±20.3 87.4±13.1 1.027 0.363 
Total cholesterol 
(mg/dl) 
192.5±41.8 180.9±33.1 188.7±40.6 0.636 0.532 
Triacylglycerol 
(mg/dl) 
147.3±67.4 123.2±55.5 146.9±66.8 1.279 0.284 
HDL** 
(mg/dl) 
38.7±10.3 40.8±11.1 40.9±11.6 0.358 0.700 
LDL*** 
(mg/dl) 
124.3±11.6 115.6±31.1 118.6±37 0.432 0.651 




4.5 Insulin Categories in relation to different                             
biochemical parameters of cases 
The relations of Insulin to the studied biochemical parameters of cases are 
illustrated in Table 4.10. Insulin level  was classified in three categories: <9, 9-
18 and >18 ìIU/mL. A total number of 50 (61%) patients were 
hyperinsulinemic  (insulin level ≥9 ìIU/mL). The increases in the mean levels 
of insulin throughout the three categories of <9, 9-18 and >18 were 
significantly associated with increasing glucose levels (F=5.619, P=0.005). On 










Table 4.10. Insulin Categories in relation to different biochemical 
parameters of cases 

















88.2±18.7 89.1±18.7 112.5±34.3 5.619 0.005 
TSH* 
(ìIU/mL) 
1.2±1.17511 1.5±1.3 1.2 ±1.4 0.184 0.832 
Total cholesterol 
(mg/dl) 
188.1±37.8 187±38.9 185.8 ±44.6 0.015 0.985 
Triacylglycerol 
(mg/dl) 
135.5±65.6 142.5±64.1 138.4±61 0.110 0.896 
HDL** 
(mg/dl) 
40.7±11.7 40.7 ±10.9 34.9±6.8 1.018 0.366 
LDL*** 
(mg/dl) 
120.5±33 117.8 ±37.5 123.4±32.3 0.108 0.898 
TSH*: Thyroid stimulating hormone, HDL**: High density lipoprotein, LDL***: Low density 
lipoprotein 
 
4.6 Categories of thyroid stimulating hormone in 
relation to different  biochemical parameters of cases 
Table 4.11 represents the relation between TSH and the studied biochemical 
parameters including, glucose, total cholesterol, triglycerides, HDL and LDL of 
cases. There was no significant relation between these parameters and the 
different TSH levels ( P>0.05). 
Table 4.11. Categories of TSH versus glucose and lipid profile  

















89±27.9 89±14.5 92.2±22.3 0.129 0.879 
Total cholesterol 
(mg/dl) 
192.2±35.2 188.8±35.4 182.3±45.1 0.384 0.682 
Triacylglycerol 
(mg/dl) 
143.4±71 144.3±60.4 129.4±64.9 0.473 0.625 
HDL** 
(mg/dl) 
37.3±9 41±10.9 40.7±12.1 0.708 0.496 
LDL*** 
(mg/dl) 
126.5±29 118.9±35.1 115.9±38.3 0.484 0.618 
HDL**: High density lipoprotein, LDL***: Low density lipoprotein 
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4.7 Correlation between insulin levels with glucose 
and lipid profile of cases 
Table 4.12 shows the correlation between insulin levels with glucose and lipid 
profile of cases. Insulin level showed strong positive correlation with glucose 
level (r=0.470). This correlation was significant with P=0.000 (Figure 4.1). 
However, a very weak correlations were found with other parameters. 
 










                       HDL**: High density lipoprotein, LDL***: Low density lipoprotein 
 
 
        Figure 4.1. Correlation of insulin with glucose 
 















4.8 Correlation between TSH levels with glucose and 
lipid profile of cases 
Table 4.13 shows the correlation between TSH levels with glucose and lipid 
profile of cases. TSH level showed relatively week negative correlations with 
total cholesterol and LDL levels (r=-0.233, r=-0.227, respectively). Such 
correlations were significant with P=0.036 and P=0.041, respectively (Figure 
4.2 and Figure 4.3). However, a very weak correlations were found with other 
parameters. 
 
Table 4.13. The correlation of thyroid stimulating hormone                 









             HDL**: High density lipoprotein, LDL***: Low density lipoprotein 
 
Figure 4.2. Correlation of thyroid stimulating  hormone (TSH) 
with total cholesterol. 
























    










































The present study is a case control investigation included 82 obese 
individuals (BMI >30 kg/m2) and 82 control (non obese individuals, BMI=18.5-
24.9 kg/m2 ) matched with age. The main objective was to  assess insulin, 
thyroid stimulating hormone, glucose and lipid levels among  obese adult 
males in Gaza Governorate. To our knowledge this is the first study in Gaza 
strip that investigate the relation between obesity, insulin, TSH and lipid 
profile. The results will benefit obese individuals to be aware of the causes 
and risk factors related to their obesity and their dangerous consequences.  
 
The age of the study population was ranged from 20-40 years with a mean 
value of 27.1±5.2 for controls and 27.4 ±5.6 for cases. The results  showed 
that a low level of illiteracy was recorded among controls and cases which 
reflected a well educated community. More than one third of the study 
population were found to be unemployed reflecting the unemployment crisis in 
Gaza Strip. Giacaman et al., (2009) reported that  the unemployment in Gaza 
Strip was around 33% of the active workforce in 2007, and rose to 37% in 
2008. Such unemployment crisis is expected to exceed 50% in 2011 as a 
result of the continuous siege on economic conditions in Gaza Strip. In both 
controls and cases smokers represented 22 (26.8%) controls and 20 (24.4%) 
cases. This excluded smoking as a confounder factor of obesity. 
 
The present study showed that  the number of cases having a history of 
hyperlipidemia, reporting suddenly weight gain and trying to lose weight but 
failed were significantly higher than controls. This result indicated  that the 
above parameters associated with obesity. In addition, the present data 
showed that most cases have more obese first degree relatives compared to 
controls implying that obesity is related to genetic factors in this group. The 
relative contributions of genetics and environment to the etiology of obesity 
have been evaluated before (35,36). Although such contribution varies from 
study to another, 30% to 40% of the variance in BMI can be attributed to 
genetics and 60% to 70% to environment. In a given population, some people 
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are genetically predisposed to develop obesity, but that genotype may be 
expressed only under certain adverse environmental conditions, such as high-
fat diets and sedentary lifestyles (146) . Increasing numbers of people are 
being exposed to these adverse environmental conditions, and consequently, 
the percentage of people expressing the obesity genotype has increased. 
Such results was supported by the study findings that the number of cases 
eating large quantities of carbohydrate and lipid was significantly higher than 
controls .In addition, lower number of cases were found to have  insedentary 
lifestyles. 
 
As revealed by questionnaire, higher percentage of cases were getting fatigue 
quickly compared to controls. Getting fatigue quickly among obese individuals 
may be due to hormonal and enzymatic disturbances which affect many 
biochemical processes in the body. Also lipid accumulation in liver and 
muscles may play a critical role in the physiology of these organs, and may 
causes fatigue. In addition, lower number of cases  consumed suitable 
amount of marine food, which is a healthy diet and may promote the synthesis 
of thyroid hormones (147,148,149,150). 
 
Concerning eating habits among  the study population, the results showed 
that higher percentages  of cases ate large quantities of carbohydrate , lipid 
and just before bed time compared to their counterparts. It is common in our 
society that most people like to eat traditional sweets (Kunafa) after meals. 
Such high calories food is a risk factor for obesity. It is well documented that 
consumption of carbohydrates and lipid-rich diet contributes largely to obesity 
(41). Eating just before bed time may be  another risk factor for obesity. This 
results is in agreement with other studies (1,1) who found that eating just 
before bed time contributes to weight gain. They explained that by the idea 
that the basal metabolic rate (BMR) is low at bed time as the metabolic 
processes and energy expenditure. 
 
The physical activity among the study population showed that the number of 
cases who are  walking regularly and having active job was significantly  less 
than controls. This indicated that  practicing such activities help in  weight 
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reduction i.e. decrease obesity incidence. Such result was consistent  with a 
previous study which proved that sedintary lifestyle and inactive job causes 
obesity. The etiology of obesity was explained on the basis of  low metabolism 
and low oxygen consumption (40).  
 
Results presented here also indicated that the mean levels of insulin and 
glucose were significantly higher in cases than in controls. These findings 
were in agreement with other studies (1). It is worth mentioning that  50 
cases were hyperinsulinimic and 6 cases were hyperglycemic. All 
hyperglycemic cases  were hyperinsulinimic but  not vice versa. Only one 
individual in the control group was hyperglycemic and hyperinsulinimic. 
Hyperinsulinemia may be due to development of insulin resistance 
(6,7,,). However, genetic or other deep studies to investigate the 
presence of mutations or other changes in the insulin receptors shape are 
needed. Most cases with insulin resistance are able to secrete enough insulin 
to maintain non-diabetic glucose levels. Some cases will go on to develop 
overt type 2 diabetes (1). It is known  that obesity is a risk factor for 
diabetes (6). However, the majority, even if they do not develop diabetes, are 
still at significantly increased risk for heart attack, stroke and other diseases 
(1,15). Concerning TSH, results showed lower levels of TSH in cases than 
in controls.  From the general view of the results there was only one patient 
who had TSH value higher than normal range, and also another one in control 
group . 
 
The present results showed that the mean levels of total cholesterol, 
triacylglycerol and LDL were increased in cases compared to controls. Such 
values reached significant value for triglycerides. These results were in 
consistent with the previous studies (12,13,14,15). The  higher concentrations 
of serum lipids in cases is mainly due to the observed insulin resistance 
developed in obese individuals. Several mechanisms whereby insulin 
resistance could cause an alteration in lipid metabolism have been described. 
Hyperinsulinemia is known to enhance hepatic very-low-density lipoprotein 
synthesis and thus may directly contribute to the increased plasma 
triacylglycerol and LDL cholesterol levels (15). Resistance to the action of 
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insulin on lipoprotein lipase in peripheral tissues may also contribute to the 
elevated triacylglycerol and LDL cholesterol levels (15,15) . In contrast, the 
mean level of HDL was significantly higher in controls than in cases. Lipid 
abnormalities had been reported in obese adults, who had elevated 
triacylglycerol and LDL cholesterol and low levels of HDL cholesterol 
(1,1) . In addition, insulin resistance observed in the present study might 
also be  implicated in the association between obesity and dyslipidemia (1). 
The lower physical activity reported by cases may further contributes to lower 
level of HDL and higher level of LDL observed in the present study.  
 
BMI was  a major criterion in the selection of study population: case group  
was selected to be over 30 kg/m2 and control group between 18.5-24.9 kg/m2  
(47). In order to make precise relations with biochemical parameters, BMI of 
individuals in case group was classified into three categories:  grade1, grade 
2 and grade 3. There was no statistical significant correlations between the 
studied biochemical parameters including insulin, glucose, TSH, total 
cholesterol, triacylglycerol, LDL and HDL among different grades of obesity. 
This reflects a narrow range of change of such parameters among different 
grades of obesity. This point needs further investigation. 
 
To investigate the relation of Insulin to the studied biochemical parameters 
glucose, TSH, total cholesterol, triglyceride, LDL and HDL of cases, insulin 
level  was classified into three categories: <9, 9-18 and >18 ìIU/mL. The 
observed  increases in the mean levels of insulin throughout the three 
categories were significantly associated with increasing glucose levels 
whereas the relation of insulin with other parameters was not significant. This 
result was supported by strong positive correlation between insulin and 
glucose levels and a weak correlations with other parameters. Simultaneous 
increase in insulin and glucose levels in obese individuals might result from 
development of insulin resistance (6,7,,). Most cases with insulin 
resistance are able to secrete enough insulin to maintain non-diabetic glucose 
levels. Some cases will go on to develop overt type 2 diabetes (). 
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The present study classified TSH levels into three categories (<0.5, 0.5-1.5, 
>1.5 ìIU/mL) and then  assessed its relation with the studied biochemical 
parameters  including glucose, total cholesterol, triacylglycerol, LDL and HDL. 
There was no significant relation between different levels of TSH and the 
studied parameters. However, the correlation statistics showed relatively 
weak  negative correlation between TSH and  total cholesterol and  LDL 
levels. This negative correlation  may be explained on the basis that increase 
in TSH may be due to increase in thyroid hormones which consequently 
decrease the concentrations of cholesterol, phospholipids and    triacylglycerol 
in plasma(). Similar results where obtained in obese individuals  
(1,1,16). Measurement of serum levels of TSH has been a consistent 
component of the clinical studies on the relationship between thyroid function 
and adiposity. The conclusion from some of these studies has been that 
weight gain increases serum levels of TSH; yet, others showed no 
relationship between TSH and body weight (16,16, 16). 
 





























6. Conclusion and recommendations 
6.1 Conclusion 
1. Obesity is a multifactorial disease associated with history of hyperlipidemia, 
weight gain and family history. 
2. Getting fatigue quickly, muscle weakness and consumption of marine food, 
and large quantities of carbohydrates and lipids-rich food were related to obesity.    
3. Physical activity particularly walking regularly and having active job protect 
against the development of obesity.  
4. The mean levels of insulin and glucose were significantly increased in obese 
individuals compared to controls. In contrast, the mean levels of TSH were lower 
in obese individuals. 
5. The mean levels of total cholesterol, triglycerides and LDL were increased in         
obese individuals compared to controls, whereas the mean level of HDL was 
significantly decreased in obese individuals. 
6. No significant relation was found between the studied biochemical parameters 
including insulin, TSH, glucose, total cholesterol, triglyceride, LDL and HDL, and  
different grades of obesity. 
7. The increases in the mean levels of insulin were significantly associated with 
increasing glucose levels . 
8.  No significant relation was found between the studied biochemical parameters 
and different TSH levels. 
9.  Insulin levels showed strong positive correlation with glucose level whereas 











6.2  Recommendations 
1. Obese people are advisable to change their dietary lifestyle and habits. 
2. Physical activity particularly walking and active lifestyle are recommended . 
3. Insulin test is a very important test for obese individuals; this test may 
predict if the obese person is pre-diabetic or not. Other genetics tests are 
needed to ascertain insulin resistance.  
4. Frequent monitoring of total cholesterol, triglyceride, LDL and HDL is 
recommended in obese individuals. 
6. Health educational programs focusing on risk factors of obesity and its 
dangerous consequences are highly appreciated. 
7. More research is needed to explore other risk factors which contributes to 
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Questionnaire about, insulin, TSH and lipid levels among obese adult 
male in Gaza Governorate. 
Demographic information: 
Name: Age:..              
Occupation:Address 






Question Yes No 
1-have you been  treated for thyroid problems  in the past   
2-Do you get fatigued   
3-Do you have decreased sweating   
4-Do you suffer from muscle weakness   
5-Do you have slow heart rate   
6-Do you consume  suitable  quantities of any of the marine 
foods 
  
7-Do you have difficulty in concentrating or remembering 
things 
  
8-Do you sleep easily   
9-When you wake up do you feel lazy   
10-Is any of your relatives obese   
11-Do you eat carbohydrate or lipid  (pie, cake, candy &ice 
cream) more than other food 
  
12- Do you eat just before bed time   
13- Do you snack between meals   
14-Do you have hyperlipidemia (high cholesterol or 
triglyceride) 
  
15-Do you gain weight inappropriately   
16-Do you try to lose weight but you fail   
17-Do you make exercise(any kind of games) regularly   
18-Do you walk regularly   
19-Does your job involve tasks that routinely keep you 
physically active 
  
20-Are you smoker   
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